Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

NCT05009017 · clinicaltrials.gov ↗

UNKNOWN

Status

272

Enrollment

OTHER

Sponsor class

Conditions

Biosimilar

Interventions

DRUG: Bevacizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences